APD811-301 A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. Primary Objective is to compare the effect of ralinepag versus placebo in subjects with standard of care or PAH-specific background therapy on disease progression and achievement of a satisfactory clinical response in subjects with WHO Group 1 PAH.

Scholars @ ECU